ABT

NYSE

ABBOTT LABORATORIES

Latest disclosureOctober 2, 2026

Insider score Why 23?: 23/ 100
Qualifying buys · 30d: $0

3 purchases · 4 sales

Price by TradingView

Insider transactions 49

Limited filing history

Filters

Last 30 daysNo qualifying insider buying. No qualifying insider sales.

Purchase disclosed

John G. Stratton

Director

Common shares without par value

Reported value: $173.64K
Reported price: $86.82 / share

Purchase disclosed

Daniel J. Starks

Director

Common shares without par value

Reported value: $926.54K
Reported price: $92.6537 / share

Purchase disclosed

Philip P. Boudreau

EVP AND CFO

Common shares without par value

Reported value: $201.3K
Reported price: $91.50 / share

Reporting insider	Security / transaction	Amount / price	Value	Traded / disclosed	Source
Director	Common shares without par valuePurchase	2,000$86.82 / share	$173.64K	May 7Filed Jun 18 · 42d later	SEC filing
Director	Common shares without par valuePurchase	10,000$92.65 / share	$926.54K	Apr 27Filed Apr 28 · 1d later	SEC filing
EVP AND CFO	Common shares without par valuePurchase	2,200$91.50 / share	$201.3K	Apr 23Filed Apr 27 · 4d later	SEC filing

Congress transactions 26

All Congress filings

Sale disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a sale for a spouse.

Richard W. AllenReporting House member

Reported amount: $15,001 – $50,000Reported range; exact amount not disclosed.
Trade date: July 14, 2026

Sale disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a sale for the member.

Richard Dean Dr McCormick official portrait

Richard Dean Dr McCormickReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: July 30, 2026

Sale disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a sale for a spouse.

Mike KellyReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: July 17, 2026

Full sale disclosed

Abbott Laboratories Common Stock · Stock

The filing reports a full sale for the member.

AAAlan ArmstrongReporting Senate member

Reported amount: $15,001 – $50,000Reported range; exact amount not disclosed.
Trade date: March 27, 2026

Sale disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a sale for the member.

Rick LarsenReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: July 8, 2026

Purchase disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a purchase for the member.

Richard Dean Dr McCormickReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: June 12, 2026

Purchase disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a purchase for the member.

Richard Dean Dr McCormickReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: June 12, 2026

Purchase disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a purchase for the member.

Gilbert CisnerosReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: June 16, 2026

Sale disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a sale for a joint account.

Julie JohnsonReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: May 12, 2026

Sale disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a sale for the member.

Gilbert CisnerosReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: May 15, 2026

Sale disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a sale for a spouse.

Richard W. AllenReporting House member

Reported amount: $15,001 – $50,000Reported range; exact amount not disclosed.
Trade date: April 16, 2026

Partial sale disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a partial sale for a joint account.

Josh GottheimerReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: May 27, 2026

Exchange disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports an exchange for the member.

Laura FriedmanReporting House member

Reported amount: $1,001 – $15,000Reported exchange amount; not a valuation of shares received.
Trade date: March 24, 2026

Purchase disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a purchase for the member.

Richard Dean Dr McCormickReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: March 19, 2026

Partial sale disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a partial sale for the member.

Gilbert CisnerosReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: February 10, 2026

Purchase disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a purchase for the member.

Thomas H. Kean JrReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: January 29, 2026

Sale disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a sale for a joint account.

Julie JohnsonReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: December 18, 2025

Sale disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a sale for the member.

Julia LetlowReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: December 8, 2025

Purchase disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a purchase for the member.

Julia LetlowReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: October 23, 2024

Partial sale disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a partial sale for the member.

Gilbert CisnerosReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: December 19, 2025

Sale disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a sale for the member.

Byron DonaldsReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: December 4, 2025

Sale disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a sale for a spouse.

Byron DonaldsReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: December 4, 2025

Purchase disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a purchase for the member.

Gilbert CisnerosReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: November 18, 2025

Partial sale disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a partial sale for a joint account.

Julie JohnsonReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: November 13, 2025

Purchase disclosed

Abbott Laboratories Common Stock (ABT) · Stock

The filing reports a purchase for the member.

Richard Dean Dr McCormickReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: November 5, 2025

Showing the latest 25 of 26 disclosed trades. Show all 26 trades

Why this buying score?

Qualifying common-equity purchase value

$325,369 of common-equity purchase value after transaction-age decay across 180 days.

+12 pts

Distinct buying groups

3 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.

+5 pts

CFO purchase

Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.

+3 pts

Material reported holdings increase

At least one row increased reported same-security holdings by 10% or established a new reported position; indirect interests may overlap.

+3 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0000001800
Latest public acceptance: Oct 2, 2026, 08:11 PM UTC
Score calculated: Oct 7, 2026, 12:03 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.

Reporting insider

Security / transaction

Amount / price

Value

Traded / disclosed

Source

Director

Common shares without par valuePurchase

2,000$86.82 / share

$173.64K

May 7Filed Jun 18 · 42d later

SEC filing

Director

Common shares without par valuePurchase

10,000$92.65 / share

$926.54K

Apr 27Filed Apr 28 · 1d later

SEC filing

EVP AND CFO

Common shares without par valuePurchase

2,200$91.50 / share

$201.3K

Apr 23Filed Apr 27 · 4d later

SEC filing

Why this buying score?

Qualifying common-equity purchase value

$325,369 of common-equity purchase value after transaction-age decay across 180 days.

+12 pts

Distinct buying groups

3 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.

+5 pts

CFO purchase

Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.

+3 pts

Material reported holdings increase

At least one row increased reported same-security holdings by 10% or established a new reported position; indirect interests may overlap.

+3 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0000001800
Latest public acceptance: Oct 2, 2026, 08:11 PM UTC
Score calculated: Oct 7, 2026, 12:03 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.